Carbohydrate vaccines as immunotherapy for cancer

Immunology and Cell Biology

Volumn 83, Issue 4, 2005, Pages 418-428

  Slovin, Susan F ^a   Keding, Stacy J ^a   Ragupathi, Govind ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer vaccine; Carbohydrate vaccine; Immunotherapy

Indexed keywords

CANCER VACCINE; CARBOHYDRATE ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; QS 21; SAPONIN; TUMOR ANTIGEN;

ANTIGEN RECOGNITION; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; NONHUMAN;

ANIMALS; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; CANCER VACCINES; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; VACCINES, CONJUGATE;

EID: 22944474953     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2005.01350.x     Document Type: Article

References (79)

1. Livingston PO, Wong GY, Adluri S et al. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Onc. 1994; 12: 1036-44.
2. Flexners S. The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J. Exp. Med. 1913; 17: 553-76.
3. Heidelberger M, Avery OT. The soluble specific substance of pneumococcus. J. Exp. Med. 1923; 38: 73-9.
4. Kayhty H, Eskola J, Peltola H, Stout MG, Samuelson JS, Gordon LK. Immunogenicity in infants of a vaccine composed to Haemophilus influenzae type b capsular polysaccharide mixed with DPT or conjugated to diphtheria toxoid. J. Infect. Dis. 1987; 155: 100-6.
5. Glunz PW, Hintermann S, Williams LJ et al. Design and synthesis of Le(y)-bearing glycopeptides that mimic cell surface Le(y) mucin glycoprotein architecture. J. Am. Chem. Soc. 2000; 122: 7273-9.
6. Lloyd KO. Blood group antigen expression in epithelial tumors: Influence of secretor status. In: Reading CL, Hakomori S-I, Marcus DM (eds). Altered Glycosylation Tumor Cells. New York: Alan R. Liss, 1998: 235-43.
7. Zhang S, Zhang HS, Cordon-Cardo C et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry. II. Blood group-related antigens. Int. J. Cancer 1997; 73: 50-6.
8. Zhang S, Cordon-Cardo C, Zhang HS et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int. J. Cancer 1997; 73: 42-9.
9. Gilewski T, Ragupathi G, Bhuta S et al. Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial. Proc. Natl Acad. Sci. USA 2001; 98: 3270-5.
10. Ragupathi G, Slovin SF, Adluri S et al. A fully synthetic globo H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: A proof of principle. Angew. Chem. Int. Ed. Engl. 1999; 38: 563-6.
11. Slovin SF, Ragupathi G, Adluri S et al. Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Natl Acad. Sci. USA 1999; 96: 5710-15.
12. Ragupathi G, Deshpande PP, Coltart DM et al. Constructing an adenocarcinoma vaccine. Immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies. Int. J. Cancer 2002; 99: 207-12.
13. Ragupathi G, Howard L, Cappello S et al. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl) cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells. Cancer Immunol. Immunother. 1999; 48: 1-8.
14. Coltart DM, Royyuru AK, Williams LJ et al. Principles of mucin architecture: Structural studies on synthetic glycopeptides bearing clustered mono-, di-, tri-, and hexasaccharide glycodomains. J. Am. Chem. Soc. 2002; 124: 9833-44.
15. Live DH, Williams LJ, Kuduk SD et al. Probing cell-surface architecture through synthesis: An NMR-determined structural motif for tumor-associated mucins. Proc. Natl Acad. Sci. USA 1999; 96: 3489-93.
16. Markl J, Lieb B, Gebauer W, Altenhein B, Meissner U, Harris JR. Marine tumor vaccine carriers: Structure of the molluscan hemocyanins KLH and HtH. J. Cancer Res. Clin. Oncol. 2001; 127: R3-R9.
17. Ragupathi G, Cappello S, Yi SS et al. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. Vaccine 2002; 20: 1030-8.
18. Goodman LA, Livingston PO, Walkley SU. Ectopic dendrites occur only on cortical pyramidal cells containing elevated GM2 ganglioside in alpha-mannosidosis. Proc. Nat. Acad. Sci. USA 1991; 88: 11330-4.
19. Ragupathi G, Coltart DM, Williams LJ et al. On the power of chemical synthesis: Immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines. Proc. Natl Acad. Sci. USA 2002; 99: 13699-704.
20. Livingston PO. Approaches to augmenting the immunogenicity of melanoma gangliosides: From whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol. Rev. 1995; 145: 147-66.
21. Tai T, Cahan LD, Tsuchida T, Saxton RE, Irie RF, Morton DL. Immunogenicity of melanoma-associated gangliosides in cancer patients. Int. J. Cancer 1995; 35: 607-12.
22. Ravindranath MH, Morton DL. Immunogenicity of membrane-bound gangliosides in viable whole-cell vaccines. Cancer Invest. 1997; 15: 491-9.
23. Kuhn CA, Hanke CW. Current status of melanoma vaccines. Dermatol. Surg. 1997; 23: 649-54.
24. Ravindranath MH, Morton DL. Role of gangliosides in active immunotherapy with melanoma vaccine. Int. Rev. Immunol. 1991; 7: 303-29.
25. Jones PC, Sze LL, Liu PY, Morton DL, Irie RF. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J. Natl Cancer Inst. 1981; 66: 249-54.
26. Livingston PO, DeLeo AB, Jones M, Oettgen HF. Comparison of approaches for augmenting the serologic response to the individually specific methylcholanthrene-induced sarcoma-Meth A: Pretreatment with cyclophosphamide is most effective. J. Immunol. 1983; 131: 2601-5.
27. Livingston PO, Ritter G, Srivastava P et al. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res. 1989; 49: 7045-50.
28. Livingston PO, Calves MJ, Helling F, Zollinger WD, Blake MS, Lowell, GH. GD3/proteosome vaccines induce consistent IgM antibodies against the ganglioside GD3. Vaccine 1993; 11: 1199-204.
29. Ritter G, Ritter-Boosfeld E, Adluri R et al. Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients with malignant melanoma. Int. J. Cancer 1995; 62: 668-72.
30. Ritter G, Boosfeld E, Adluri R et al. Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma. Int. J. Cancer 1991; 48: 379-85.
31. Ritter G, Boosfeld E, Calves MJ, Oettgen HF, Old LJ, Livingston PO. Antibody response to immunization with purified GD3 ganglioside and GD3 derivatives (lactones, amide and gangliosidol) in the mouse. Immunobiology 1990; 182: 32-43.
32. Livingston PO, Ritter G, Calves MJ. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse. Cancer Immunol. Immunother. 1989; 29: 179-84.
33. Wang ZG, Williams LJ, Zhang XF et al. Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: Isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens. Proc. Natl Acad. Sci. USA 2000; 97: 2719-24.
34. Kudryashov V, Ragupathi G, Kim IJ et al. Characterization of a mouse monoclonal IgG3 antibody to the tumor-associated globo H structure produced by immunization with a synthetic glycoconjugate. Glycoconj. J. 1998; 15: 243-9.
35. Helling F, Shang A, Calves M et al. GD3 vaccines for melanoma: Superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res. 1994; 54: 197-203.
36. Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 1991; 146: 431-7.
37. Helling F, Zhang S, Shang A et al. GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 1995; 55: 2783-8.
38. Kitamura K, Livingston PO, Fortunato SR et al. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc. Natl Acad. Sci. USA 1995; 92: 2805-9.
39. Livingston P, Zhang S, Adluri S et al. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies. Cancer Immunol. Immunother. 1997; 43: 324-30.
40. Livingston PO, Adluri S, Helling F et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet hemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 1994; 12: 1275-80.
41. Chapman PB, Morissey DM, Panageas KS et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: A dose-response study. Clin. Cancer Res. 2000; 6: 874-9.
42. Kirkwood JM, Ibrahim J, Lawson DH et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J. Clin. Oncol. 2001; 19: 1430-6.
43. Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon Alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma. Results of Intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 2001; 19: 2370-80.
44. Ragupathi G, Meyers M, Adluri S, Ritter G, Livingston PO. Phase I trial with GD3-lactone-KLH conjugate and immunological adjuvant QS-21 vaccine with malignant melanoma. Proc. Am. Assoc. Cancer Res. 1997; 38: 3981a.
45. Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston PO. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int. J. Cancer 2000; 85: 659-66.
46. Cappello S, Liu NX, Musselli C, Brezicka FT, Livingston PO, Ragupathi G. Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin results in antibodies against human small-cell lung cancer cells. Cancer Immunol. Immunother. 1999; 48: 483-92.
47. Brezicka T, Bergman B, Olling S, Fredman P. Reactivity of monoclonal antibodies with ganglioside antigens in human small cell lung cancer tissues. Lung Cancer 2000; 28: 29-36.
48. Vangsted AJ, Clausen H, Kjeldsen TB et al. Immunohistochemical detection of a small cell lung cancer-associated ganglioside (FucGM1) antigen in serum. Cancer Res. 1991; 51: 2879-84.
49. Dickler MN, Ragupathi G, Liu NX et al. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin. Cancer Res. 1999; 5: 2773-9.
50. Krug LM, Ragupathi G, Hood C et al. Vaccination of patients with small cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin. Clin. Cancer Res. 2004; 10: 6094-100.
51. Canevari S, Fossati G, Balsari A, Sonnino S, Colnaghi MI. Immunochemical analysis of the determinant recognized by a monoclonal antibody (MBr1) which specifically binds to human mammary epithelial cells. Cancer Res. 1983; 43: 1301-5.
52. Menard S, Tagliabue E, Canevari S, Fossati G, Golnaghi MI. Generation of monoclonal antibodies reacting with normal and cancer cells of human breast. Cancer Res. 1983; 43: 1295-300.
53. Bilodeau MT, Park TK, Hu S et al. Total synthesis of a human breast tumor associated antigen. J. Am. Chem. Soc. 1995; 117: 7840-1.
54. Kim IJ, Park TK, Hu S et al. Defining the molecular recognition of globo H (human breast cancer) antigen through probe structures prepared by total synthesis. J. Org. Chem. 1995; 60: 7716-17.
55. Ragupathi G, Park TK, Zhang S et al. Immunization of mice with a fully synthetic globo-H antigen results in antibodies against human cancer cells: A combined chemical-immunological approach to the fashioning of an anticancer vaccine. Angew. Chem. Int. Ed. Engl. 1997; 36: 125-8.
56. Ragupathi G, Slovin SF, Adluri S et al. A fully synthetic globo H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: A proof of principle. Angew. Chem. Int. Ed. Engl. 1999; 38: 563-6.
57. Slovin SF, Ragupathi G, Adluri S et al. Carbohydrate vaccine in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc. Natl Acad. Sci. USA 1999; 96: 5710-15.
58. b blood group determinants and of H-type I and H-type II oligosaccharides. J. Am. Chem. Soc. 1995; 117: 5701-11.
59. y-protein conjugate vaccine: Clinical and serological results. Int. J. Cancer 2000; 87: 79-85.
60. Samuel J, Noujaim AA, MacLean GD, Suresh MR, Longenecker BM. Analysis of human tumor associated Thomsen-Friedenreich antigen. Cancer Res. 1990; 50: 4801-8.
61. Adluri S, Helling F, Ogata S et al. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol. Immunother. 1995; 41: 185-92.
62. Apostolopoulos V, McKenzie IFC. Cellular mucins: Targets for immunotherapy. Crit Rev. Immunol. 1994; 14: 293-309.
63. Fung PYS, Madej M, Koganty RR, Longenecker BM. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res. 1990; 50: 4308-14.
64. Singhal A, Fohn M, Hakomori S. Induction of alpha-N-acetylgalactosamine- O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res. 1991; 51: 1406-11.
65. Miles DW, Towlson KE, Graham R et al. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br. J. Cancer 1996; 74: 1292-6.
66. Koganty RR, Reddish MA, Longenecker BM. Glycopeptide- and carbohydrate-based synthetic vaccines for the immunotherapy of cancer. Drug Discov. Today 1996; 1: 190-8.
67. Slovin SF, Ragupathi G, Fernandez C et al. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: Clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol. Immunother. (in press).
68. Slovin SF, Ragupathi G, Musselli C et al. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: Clinical trial results with α-N-acetylgalactosamine-o-serine/ threonine (Tn) conjugate vaccine. J. Clin. One. 2003; 21: 4292-8.
69. Longenecker BM, Reddish M, Koganty R, MacLean GD. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. Ann. New York Acad. Sci. 1993; 690: 276-91.
70. MacLean GD, Reddish M, Koganty RR et al. Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant. Cancer Immunol. Immunother. 1993; 36: 215-22.
71. Zhang S, Walberg LA, Ogata S et al. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res. 1995; 55: 3364-8.
72. Ragupathi G, Howard L, Cappello S et al. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl) cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells. Cancer Immunol. Immunother. 1999; 48: 1-8.
73. Ragupathi G, Koganty RR, Qiu DX, Lloyd KO, Livingston PO. A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: Synthesis of sialyl Tn KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. Glycoconj. J. 1998; 15: 217-21.
74. Dickler M, Gilewski T, Ragupathi G et al. Vaccination of breast cancer patients with no evidence of disease with sialyl Tn cluster-keyhole limpet hemocyanin conjugate plus adjuvant QS-21: Preliminary results. Proc. Am. Soc. Clin. Oncol. 1997; 16: 439a.
75. MacLean GD, Miles DW, Rubens RD, Reddish MA, Longenecker BM. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J. Immunother. Emphasis Tumor Immunol. 1996; 19: 309-16.
76. MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J. Immunother. Emphasis Tumor Immunol. 1996; 19: 59-68.
77. Keding SJ, Danishefsky SJ. Prospects for total synthesis: A vision for a totally synthetic vaccine targeting epithelial tumors. Proc. Natl Acad. Sci. USA 2004; 101: 11937-42.
78. Slovin SF, Ragupathi G, Fernandez C et al. A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: A study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 or QS-21. Vaccine 2005; 23: 3114-22.
79. Slovin S, Ragupathi G, Clarke T et al. Multivalency in a Phase II prostate cancer vaccine trial: Are more antigens better?. Proc. Am. Soc. Clin. Onc. 2003; 22: 167 (Abstract 671).